0000921895-23-001766.txt : 20230731
0000921895-23-001766.hdr.sgml : 20230731
20230731193950
ACCESSION NUMBER: 0000921895-23-001766
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230726
FILED AS OF DATE: 20230731
DATE AS OF CHANGE: 20230731
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Lazar David E.
CENTRAL INDEX KEY: 0001932843
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-13341
FILM NUMBER: 231129104
MAIL ADDRESS:
STREET 1: VILLA 1, 14-43RD STREET
STREET 2: JUMEIRAH 2
CITY: DUBAI
STATE: C0
ZIP: 00000
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: TITAN PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0000910267
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 943171940
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 400 OYSTER POINT BLVD
STREET 2: SUITE 505
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 6502444990
MAIL ADDRESS:
STREET 1: 400 OYSTER POINT BLVD
STREET 2: SUITE 505
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
form413531laz_07282023.xml
OWNERSHIP DOCUMENT
X0508
4
2023-07-26
0
0000910267
TITAN PHARMACEUTICALS INC
TTNP
0001932843
Lazar David E.
VILLA 1, 14-43RD STREET
JUMEIRAH 2
DUBAI
C0
00000
UNITED ARAB EMIRATES
1
1
0
0
Chief Executive Officer
0
Common Stock
2023-07-26
4
A
0
100000
0
A
100000
D
The shares reported in this transaction represent Unrestricted Stock Awards pursuant to the Issuer's Fourth Amended and Restated 2015 Omnibus Equity Incentive Plan that vested immediately on the date of grant.
/s/ David E. Lazar
2023-07-31